Navigation Links
Top 200 Biopharmaceuticals Industry Report (Global)

NEW YORK, Jan. 12, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Top 200 Biopharmaceuticals Industry Report (Global)

The Global Biopharmaceuticals Industry Report

Plimsoll Publishing Ltd.

This report is an in-depth financial evaluation of the Global Biopharmaceuticals Industry. Using the unique Plimsoll method of analysis, each of the top 200 Biopharmaceuticals Companies is individually assessed and ranked against each other and compared to industry averages. Using the most up-to-date financial information available, the two-page per company analysis provides detailed financial analysis for each organisation, including details of;

• Sales growth

• Trading stability

• Profitability

• Employee performance

• Level of debt

• Gearing ratio's

• Creditor Exposure

• Performance ratio's

• Overall financial rating

Results are shown in graphical, numeric and narrative forms, and all individual analysis are measured in both the company's own currency, and USD ($) for ease of use. These individual analyses highlight a company's success just as easily as it can emphasise its vulnerability.

Along with individual company information, this report also contains an assesment of the market, based on the companies analysed. This key information identifies;

• Best trading partners (based on commercial and financial strength)

• Sales growth (highest sales, growth rate, size of market based on the companies analysed, average growth)

• Profitability (Profit return on assets, pre-tax profit margins, industry average)

• Fastest growing companies (performance matrix)

Companies can change at an alarming rate in a very short space of time, so it is vital that you keep up-to-date with any changes to your market, and how those changes can affect you. This report can provide you with an in-depth look at your industry, highlight new market opportunities and provide important information to help develop accurate strategic business plans. Whether you wish to benchmark your own company's results, study the industry in more depth or have a vast array of industry intelligence at your disposal, this report is the ideal resource.

This extensive report is broken into two parts:

1. A complete financial assessment of the market, based on the companies analysed

2. An individual financial performance analysis of each company (2 pages per company)

Specific areas included in the market assessment include;

Section 1 - Best Trading Partners (based on commercial and financial strength)

1.1a – Best Trading Partners definition and industry top 5 list

1.1b – Performance matrix (Financial Strength Vs Sales Growth)

1.1c – List of Best Trading Partners in the industry

Section 2 - Sales & Market Performance

2.1 – Sales Growth

2.1a – 4 year trend analysis

2.1b – Industry Average Sales Growth

2.1c – Sales Growth Ranking Table

2.1d – Top 50 Companies ranked by Market Share

2.2 – Sales Return on Assets

2.2a – 4 year trend analysis

2.2b – Sales return on total assets

2.2c – Sales return on assets ranking table

2.2d – Top 50 companies' sales return on assets

Section 3 – Profitability

3.1 – Pre-tax profit margin

3.1a – Pre-tax profit margin 4 year trend analysis

3.1b – Industry Average pre-tax profit margin

3.1c – Pre-tax profit margin ranking table

3.1d – Top 50 companies actual pre-tax profit

3.2 - Pre-tax profit return on total assets

3.2a - Pre-tax profit return on total assets 4 year trend analysis

3.2b – Industry average pre-tax profit return on total assets

3.2c – Pre-tax profit return on total assets ranking table

3.3 - Profitability

3.3a – Profitability industry average

4. 0 – How to Use

5.0 – Individual Company Analysis

The individual company assessment gives a complete financial picture of each company listed, including a narrative summary of the analysis. One of our key indicators is the Plimsoll Chart which combines several performance figures to give an overall measurement of the financial strength of any company. The Plimsoll chart is complied through the analysis of several different areas, including;

Sales Growth, Trading Stability, Profitability, Working Capital, Gearing and Immediate Liquidity

As all measurements are standardised, in one report you can quickly compare like with like for every major company in your industry. The accounts of each company appear in its own currency and US$ to allow comparison.

Each individual company analysis includes:

• A full four year financial assessment, Debtor days analysis, Latest sales/profitability rankings.

• Employee Performance Analysis, Comparisons against industry average.

• Overall company financial rating as read in the Plimsoll Chart, Industry ranking matrix.

• Company analysis written summary.

Other information in the report includes;

• Details of the Plimsoll Model

• Definition of Terms

• List of Shareholders

• Global Index by region

• Ranking Analysis by sales/profits

• Companies considered but not included

• Index of companies

To order this report:

Biopharmaceutical Industry: Top 200 Biopharmaceuticals Industry Report (Global)

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
(Date:11/24/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the ... capability and technology platform company serving the pharmaceutical, biotechnology, ... China and the United States ... meeting of shareholders held today, the Company,s shareholders voted ... the previously announced agreement and plan of merger (the ...
(Date:11/24/2015)... , Nov. 24, 2015  In the pharmaceutical ... in an effort to quickly uncover new insights, tactics ... --> --> However, organizations ... market research project and ensure that all rules and ... industry standards. Another major barrier to efficiently launching market ...
(Date:11/24/2015)... Nov. 24, 2015  DILON Diagnostics and GE Healthcare ... agreement for DILON to distribute GE,s Discovery NM750b Molecular ... signing of this distribution agreement will provide Dilon,s experienced ... Imaging system and is considered an initial step in ... solutions for clinicians and their patients. ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
(Date:11/24/2015)... Los Angeles, CA (PRWEB) , ... November 24, 2015 , ... ... author explored the different restrictions and variables that determine which patients are or are ... are those patients that have a BMI over 40, are more than 100 pounds ...
(Date:11/24/2015)... ... , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, ... FDA has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls ... meet the device regulations. , Come up short in an inspection and the FDA ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... In response ... growing epidemic as deaths from prescription opioids in the United States grew 400 percent ... In 2013 alone, opioids were involved in 37 percent of all fatal drug overdoses. ...
(Date:11/24/2015)... AL (PRWEB) , ... November 24, 2015 , ... American ... announced today the opening of a holiday pop-up clinic located in Metro Atlanta’s North ... needs in a new and different way. The location is scheduled to operate through ...
Breaking Medicine News(10 mins):